In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Vivo's Deals Of The Month, October 2016

Executive Summary

In Vivo's editors pick October's most significant deals, including stealthy Carrick's big Series A and AstraZeneca's out-licensing spree. (Article free with registration.)

You may also be interested in...



Deal Watch: Takeda Seeks A Crescendo With Collaboration On New Type Of Cancer Compound

AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.

Allergan Licenses MEDI2070, As AstraZeneca Continues Non-Core Exits

Continuing its strategy to exit non-core activities, AstraZeneca's licensed Allergan global rights to its IL-23 monoclonal antibody in Phase IIb testing for moderate-to-severe Crohn’s disease and ready for Phase II studies in ulcerative colitis. Analysts say the deal makes sense for both parties.

Carrick Therapeutics Lays Foundation For 'Leading Oncology Business'

With $95m in the bank from various investors – including ARCH Ventures, Woodford Investment Management, Google Ventures and drug discovery company Evotec – recently launched Carrick Therapeutics is striving to be at the forefront of oncology companies in Europe.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel